PharmaFocus Today – Page 6 – media

Fosun Pharma and Ruizhi Pharma Reach Strategic Cooperation

On November 25th, Fosun Pharma and Ruizhi Pharma…A strategic cooperation framework agreement signing ceremony was held in Shanghai. Li Xiang, Senior Vice President and CEO of the Global R&D Center of Fosun Pharma , stated that in the future, leveraging the full-chain R&D service capabilities of Ruizhi Pharma , Fosun Pharma is expected to further improve the efficiency and quality of its drug development across various drug types, accelerate the transformation of innovative achievements, and consolidate its competitive advantage in the field of innovative medicine. At the same time, the cooperation between the two parties sets a benchmark for the industry with a “technology-driven innovation platform + service platform” model, which will help promote the efficient integration of upstream and downstream resources in the industry chain, contribute to improving the overall level of new drug development in China, and bring more high-quality treatment options to more patients. https://finance.eastmoney.com/a/202511253574517765.html
- Source: drugdu
- 62
- November 26, 2025
Aurisco’s wholly-owned subsidiary received the marketing authorization for its Estradiol Tablets

November 25 – Aurisco (605116) announced that its wholly-owned subsidiary, Yangzhou Aurisco Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging. The dosage form is tablets, with specifications as follows: each Estradiol Tablet contains 2mg of estradiol, and each Estradiol and Dydrogesterone Tablet contains 2mg of estradiol and 10mg of dydrogesterone. As of October 31, 2025, the cumulative R&D investment in this drug project by the company amounted to approximately RMB 12.64 million. This product is a dydrogesterone compound preparation originally developed by Abbott. It is used to treat perimenopausal syndrome caused by natural or surgical menopause. In 2015, the Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging, applied for by Abbott as an imported drug, was approved for marketing in China under the brand name “Femoston®”. Data from ...
- Source: drugdu
- 54
- November 26, 2025
Hengrui Pharma’s Ruikang Trastuzumab for Injection Wins Clinical Trial Approval

Beijing Business Today, Nov. 25 – Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for Ruikang Trastuzumab for Injection, approving the monotherapy clinical trial in patients with HER2-amplified solid tumors. According to the announcement, Ruikang Trastuzumab for Injection binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosomes, the toxin is released through protease cleavage, inducing cell cycle arrest and triggering tumor cell apoptosis. The released toxin exhibits high membrane permeability, enabling a bystander killing effect that further enhances anti-tumor efficacy. Ruikang Trastuzumab for Injection was approved for marketing in China in May 2025, indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one line of systemic ...
- Source: drugdu
- 57
- November 26, 2025
AI-driven drug development partnership reaches $3 billion

Merck recently announced a strategic collaboration agreement with Valo Health, potentially worth up to $3 billion, aimed at accelerating the development of innovative treatments for Parkinson’s disease using artificial intelligence (AI) and machine learning technologies. Under the terms of the agreement, Merck will make an undisclosed upfront payment to Valo Health and commit to additional payments totaling up to $3 billion upon achieving specific R&D, regulatory approvals, and commercialization milestones. The collaboration also includes R&D funding and tiered royalties on future product sales. The division of labor between the two parties is clear: Valo Health will utilize its self-developed Opal computing platform to be responsible for the early identification of drug targets and the design and optimization of candidate molecules; Merck will be responsible for subsequent clinical development, registration and application, and global commercialization. This collaborative model of “AI biotechnology company + traditional pharmaceutical company” is becoming the mainstream in ...
- Source: drugdu
- 72
- November 26, 2025
Honz Pharmaceutical Co., Ltd. has received the approval notice for the clinical trial of the cough-relieving orange-red granules drug

Beijing Business News (Reporter Ding Ning) – On the evening of November 25th, Honz Pharmaceutical Co., Ltd. (300086) issued a statement, announcing that recently, the company’s “Cough Suppressant Juhong Granules” has obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The announcement shows that Cough Suppressant Juhong Granules is a product that the company has already produced and is currently on sale. It was originally a national second-level protected traditional Chinese medicine variety (with a protection period until September 13, 2016), and its current indications are “clearing the lungs, suppressing cough, and resolving phlegm. It is used for cough with excessive phlegm, chest fullness, shortness of breath, dry throat and itchy throat caused by phlegm heat blocking the lungs.” Based on the latest clinical research and expert consensus, the company submitted a clinical trial application to add a new indication of “acute exacerbation of chronic ...
- Source: drugdu
- 53
- November 26, 2025
Novo Nordisk has released the clinical trial data of its new diabetes drug, amycretin.

Novo Nordisk has released the clinical trial data for the new diabetes drug amycretin, showing that the drug not only lowers blood sugar but also has a significant weight loss effect. The trial results indicate that the amycretin injection, administered once a week, can help patients lose up to 14.5% of their weight within 36 weeks; the oral formulation can achieve a weight loss of up to 10.1% per day. This positive news has pushed the stock price of Novo Nordisk’s US shares to rise, recovering most of the losses it suffered previously due to the failure of its Ozempic oral version to slow the progression of Alzheimer’s disease in two clinical trials. Amycretin is a key component of Novo Nordisk’s new drug portfolio, integrating two weight loss mechanisms into a single molecule, aiming to improve the company’s competitive position in the field of obesity treatment. https://finance.eastmoney.com/a/202511263574807587.html
- Source: drugdu
- 45
- November 26, 2025
Mabwell Biotech’s innovative CDH17-targeted ADC drug 7MW4911 has been successfully administered to its first patient

November 25th, Mabwell Biotechnology announced on its official WeChat account that it has developed an innovative CDH17-targeting ADC drug.(Development code: 7MW4911) The first patient was recently dosed in a Phase I/II clinical trial for advanced solid tumors. Preclinical studies showed that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors; in multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd ADCs, and it could reverse tumor progression after treatment with such ADCs, highlighting its advantages in the treatment of drug-resistant tumors. https://finance.eastmoney.com/a/202511253573547662.html
- Source: drugdu
- 65
- November 25, 2025
Approval Received for Marketing Authorization of Edoxaban Tosylate API

Jiuzhou PharmaceuticalThe announcement states that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. received chemical raw materials from the National Medical Products Administration.The company recently received the Approval Notice for Marketing Authorization of its chemical active pharmaceutical ingredient, edoxaban tosylate. This oral anticoagulant is primarily used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism. This approval indicates that the active pharmaceutical ingredient meets the relevant requirements for national drug registration and will further enrich the company’s product portfolio and enhance its market competitiveness. The above matters will not have a significant impact on the company’s performance in the short term. https://finance.eastmoney.com/a/202511243572990379.html
- Source: drugdu
- 56
- November 25, 2025
Breakthrough in Innovative Drug, “Twin-Engine” Strategy Forges New Landscape

Northeast Pharmaceutical recently stated in an interview with China Securities Journal that in recent years, the company has focused on innovation-driven strategies and deepening its core business, achieving significant results in R&D breakthroughs and business quality improvement. This has established a synergistic development pattern characterized by “breaking new ground in R&D innovation, stabilizing profitability in core business, and enhancing efficiency in asset operations.” Particularly against the backdrop of accelerating innovation and transformation in the pharmaceutical industry, the company has adopted a differentiated strategy of “consolidating the fundamental business through traditional operations while creating new growth drivers through innovative drug development.” This approach has not only safeguarded its profit baseline but also unlocked new growth potential. Recently, the company’s subsidiary, Dingcheng Peiyuan, received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration (NMPA) for its self-developed DCTY0801 Injection. Looking ahead, as the innovative drug pipeline advances and ...
- Source: drugdu
- 57
- November 25, 2025
sIPV vaccine granted approval for market, pentavalent combination vaccine granted approval for clinical trials

November 24 (NBD AI Express) — According to an update on China National Biotec Group (CNBG)’s official WeChat account, Wuhan Biological Products Institute, its subsidiary, has recently achieved significant progress in the field of pediatric vaccine development. The Sabin strain inactivated poliovirus vaccine (Vero cell) has received market approval from the National Medical Products Administration (NMPA) (Approval No.: S20250060). Simultaneously, the Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b (Conjugate) Combined Vaccine has obtained clinical trial approval (Acceptance No.: CXSL2500756). Reference：https://finance.eastmoney.com/a/202511243572908132.html
- Source: drugdu
- 54
- November 25, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.